Tip for Type 1s: Consider Lantus
A database matched baseline A1C values in 196 subjects with type 1 diabetes receiving more than four MDI per day. Ninety-eight patients transferred from NPH to Lantus, and 98 patients remained on NPH. There was no change in the short-acting insulin dose in either group. The majority of patients were well controlled, with more than 50 percent in both groups having an A1C less than 7%, the goal currently advised by the American Diabetes Association.
Severe hypoglycemia was significantly lower in the Lantus group. The weight gain was significantly higher in the NPH group at the end of the study, with no significant change in the Lantus group.
The study was funded by Sonofi-Aventis, the maker of Lantus.
—Diabetes Technology & Therapeutics, vol. 6, no. 5Click Here To View Or Post Comments